Cargando…

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Suparna, Choudhury, Shouvik, Das, Debaleena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012417/
https://www.ncbi.nlm.nih.gov/pubmed/35343208
http://dx.doi.org/10.4103/ijp.ijp_519_21
_version_ 1784687791870836736
author Chatterjee, Suparna
Choudhury, Shouvik
Das, Debaleena
author_facet Chatterjee, Suparna
Choudhury, Shouvik
Das, Debaleena
author_sort Chatterjee, Suparna
collection PubMed
description The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID-19 patients with mild-to-moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost-benefit profile shall provide useful information to the scientific community and patients.
format Online
Article
Text
id pubmed-9012417
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90124172022-04-16 An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies Chatterjee, Suparna Choudhury, Shouvik Das, Debaleena Indian J Pharmacol Review Article The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID-19 patients with mild-to-moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost-benefit profile shall provide useful information to the scientific community and patients. Wolters Kluwer - Medknow 2022 2022-03-18 /pmc/articles/PMC9012417/ /pubmed/35343208 http://dx.doi.org/10.4103/ijp.ijp_519_21 Text en Copyright: © 2022 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Chatterjee, Suparna
Choudhury, Shouvik
Das, Debaleena
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title_full An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title_fullStr An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title_full_unstemmed An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title_short An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
title_sort update of antispike severe acute respiratory syndrome coronavirus 2 (sars-cov-2) monoclonal antibodies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012417/
https://www.ncbi.nlm.nih.gov/pubmed/35343208
http://dx.doi.org/10.4103/ijp.ijp_519_21
work_keys_str_mv AT chatterjeesuparna anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies
AT choudhuryshouvik anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies
AT dasdebaleena anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies
AT chatterjeesuparna updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies
AT choudhuryshouvik updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies
AT dasdebaleena updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies